Standardisation of measurements of neurodegenerative disease biomarkers

神经退行性疾病（ndd）影响了超过900万欧洲人，对社会构成了巨大的经济负担。NDD生物标志物通过将疾病与病理过程联系起来并协助药物开发，改变了研究领域。NDD生物标志物通过使用非侵入性工具提高了诊断和预后的准确性。然而，它们在临床实践中的实施由于缺乏标准化而受到阻碍。该项目将以以前的EMPIR项目为基础，标准化生物标志物测量，协调测定制造商之间的测量，建立质量评估计划，开发和实施新的生物标志物。

Neurodegenerative disorders (NDDs) affect over nine million Europeans and constitute a large economic burden to society. NDD biomarkers have transformed the research landscape by linking diseases to pathological processes and assisting drug development. NDD biomarkers improve the accuracy of diagnosis and prognosis with the use of non invasive tools. However, their implementation in clinical practice is hampered by a lack of standardisation. This project will build on previous EMPIR projects to standardise biomarker measurements, harmonise measurements across assay manufacturers, establish quality assessment programmes, develop and implement new biomarkers.